Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
← catalyst calendarSponsored by Cellectar Biosciences, Inc. (industry) · CLRB — their whole pipeline →. With National Cancer Institute (NCI).
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50estimated
Sites
8
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-01 | actual | When the study began enrolling |
| Primary completion | May 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- High-Grade Glioma
Intervention
- Drug: CLR 131 — also filed as iopofosine I 131
Primary outcomes
what the primary-completion date above is the date OFSafety Evaluation of CLR 131
measured Assessed throughout the study to 1-year post-infusion follow-up period
Efficacy Evaluation for Progression Free Survival
measured Day 84 post-infusion follow-up period through 3 years following completion of treatment.
Permalink · CLRB's whole pipeline · Catalyst calendar · Every registered study · What changed